Ionis (IONS) Q4 2025 Earnings Transcript

Ionis reported record 2025 revenue of $944 million, up 34% year over year, and said it exceeded guidance across all operating metrics. Management guided 2026 revenue to $800 million-$825 million and non-GAAP operating loss to $500 million-$550 million, while highlighting multiple launch catalysts including olezarsen for sHTG, zilganersen for Alexander disease, and continued DAWNZERA growth. The company also raised its peak sales view for olezarsen to over $2 billion and remains on track for cash flow breakeven by 2028.

Analysis

IONS is transitioning from a “science optionality” story to a revenue mix story, and that matters more than the headline beat. The key second-order effect is that commercial launches are now starting to self-fund the pipeline flywheel: recurring product revenue plus milestone/royalty cash is reducing dependence on any single binary readout, which should compress the company’s financing overhang and support a higher quality of earnings multiple over the next 12-18 months.

The market is likely underappreciating how much the sHTG launch changes the shape of the P&L, not just the top line. Even if TRYNGOLZA temporarily gets cannibalized, the economics can still improve because the addressable pool expands materially; the important variable is whether payer access is secured before competitors can anchor pricing expectations. If management executes the launch well, the near-term revenue dip is an intentional bridge to a much larger franchise, making the stock less about quarterly execution and more about whether olezarsen can sustain adoption beyond the first wave of prescribers.

The main risk is not clinical anymore; it’s commercialization timing and pricing friction. A standard review versus priority review is worth a meaningful delta in 2026 revenue cadence, but the bigger risk is that the company over-earns enthusiasm from the market before real-world conversion in the broad indication proves durable. Investors should also watch whether the partner milestones are being mentally overcapitalized by the street; those are valuable, but they are episodic and can create a false sense of de-risking if the core launch ramps slower than expected.

Contrarian view: this is not an “all clear” rerating, it is a sequencing trade. The stock can work even if one or two catalysts slip, but the best setup is likely into any pullback on regulatory timing concerns, because the balance sheet, launch infrastructure, and multi-catalyst calendar create a cleaner 6-12 month path than the market usually gives a biotech with this many moving parts. The surprise could be less from one giant upside event and more from a steady cadence of smaller positive readouts that keeps compounding the revenue base.

Key Decisions for Investors

• Long IONS on 3-6 month horizon: buy on any post-call pullback tied to standard-review skepticism; risk/reward favors upside if sHTG approval lands in Q4 and the launch ramps into 2027.
• Sell downside protection via IONS put spread if implied vol stays elevated into FDA timing: structure to monetize event premium while limiting risk around acceptance/priority-review headlines.
• Pair trade: long IONS / short a basket of slower-growth biotech royalty names over 6-12 months, betting that IONS’ mix shifts from episodic royalties to durable commercial revenue and expands multiple quality.
• Avoid chasing GSK/NVS on the call alone; better to own IONS for operating leverage, while treating partner catalysts as upside rather than core thesis—partner royalties are helpful but not sufficiently controllable for standalone longs.
• If looking for relative value, pair long IONS against short another launch-stage biotech with one product and weaker balance sheet; IONS has better de-risked funding, multiple shots on goal, and lower dilution risk.